BMO Capital reiterated its Outperform rating on Alnylam Pharmaceuticals on Monday, maintaining a price target of $318 per share as the company’s ATTR franchise strengthens.
The stock last traded at $239.78, up 0.95%, with a market capitalization of approximately $32 billion. BMO’s target implies roughly 33% upside from current levels. The analyst cited consistent efficacy data for Amvuttra in cardiovascular and systemic manifestations, as well as in key patient subgroups, following presentations at the European Society of Cardiology Congress.
Alnylam also highlighted commercial dynamics supporting front-line leadership and sales growth during an investor event at the conference. The company emphasized TRITON-CM design features aimed at maximizing success probability for its pipeline candidates. Amvuttra and nucresiran are expected to sustain a lasting ATTR franchise with potential mega-blockbuster status, while the ex-ATTR pipeline offers additional upside.
Analysts at the ESC Congress noted solid prospects for the ATTR category, with limited impact from eplontersen data. However, concerns emerged after AstraZeneca reported a Phase 3 clinical trial failure for a silencing drug in a similar class, briefly pressuring Alnylam’s shares despite maintained confidence from firms such as Bernstein.
Current trading ranges for Alnylam’s stock sit between $230 and $536, with price targets from other firms including Canaccord Genuity at $429, Bernstein SocGen at $376, and Raymond James at $420. The company’s revenue grew 95% over the last twelve months, and InvestingPro data indicates the stock is undervalued at present levels, with net income expected to rise this year and continued profitability projected by analysts.
